Osteoporosis Targeting, Possible Breakthroughs
Da-Yong Lu* and Jin-Yu Che
School of Life Sciences, Shanghai University, Shanghai, China
*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, China.
Received:
August 25, 2021; Published: October 01, 2021
Abstract
Osteoporosis is an issue of public health concern worldwide. Currently, it is very difficult in the clinic. To face with this difficulty, the therapeutic breakthrough is a top priority. This editorial aims to discuss this hot topic of orthopedic disease.
Keywords: Osteoporosis; Clinical Trial; Personalized Medicine; Orthopedic Disease
References
- Melton J. “Hip fracture; a worldwide problem today and tomorrow”. Bone 14 (1993): S1-8.
- Lu DY and Che JY. “Osteoporosis treatments”. Clinical Biotechnology and Macrobiology2 (2019): 612-614.
- Lu DY., et al. “Osteoporosis in old women, therapeutic selection”. EC Orthopaedics7 (2018): 386.
- Choudhary D and Alam A. “Anti-osteoporotic activity of bioactive compounds from Iris germanica targeting NK-Kappa B”. EC Pharmacology and Toxicology8 (2018): 665-678.
- Marks R. “Vitamin E and osteoarthritic cartilage: Does vitamin E influence cartilage integrity?” EC Orthopaedics5 (2019): 281-294.
- Patel S. “Conservative pain management”. EC Orthopaedics8 (2018): 621-623.
- Lu DY., et al. “Osteoporosis, importance for early diagnosis and treatment”. EC Orthopaedics9 (2018): 624-625.
- Lu DY., et al. “Osteoporosis treatments for old people”. EC Orthopeadicis5 (2019): 278-280.
- Lu DY., et al. “Bone disease recovery strategies, An overview”. EC Orthopaedics1 (2019): 1-3.
- Araujo JL. “The role of the orthopedic surgeon in preventing low back pain chronification”. EC Orthopaedics 12 (2018): 809-812.
- Harsini SM and Oryan A. “Bone grafting and the materials for using in orthopaedics”. EC Orthopaedics 12 (2018): 822-833.
- Zweedijk R., et al. “Scoliosis and osteopathy”. Acta Scientific Orthopaedics 9 (2020): 30-43.
- Lu DY and Che JY. “Bone disease treatment, an editorial”. EC Orthopeadics 8 (2020): 143-145.
- Lu DY., et al. “Bone disease recovery strategies, An overview”. EC Orthopaedics 1 (2019): 1-3.
- Koleva IB and Yoshinov B. “Rehabilitation as an essential element in the clinical practice of orthopaedics and traumatology”. Acta Scientific Orthopaedics 9 (2020): 44-46.
- Lu DY., et al. “Osteoporosis treatments for old people”. EC Orthopeadicis 5 (2019): 278-280.
- Che JY and Lu DY. “Bone disease treatment, future direction”. EC Pharmacology and Toxicology 1 (2021): 7-8.
- Negm SH. “The possible protective role of powder cuttlefish bone, crab shell and eggshell on osteoporotic rats”. Journal of Food and Dairy Sciences10 (2018): 111-121.
- Mobasheri A and Shakbael M. “Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis”. Annals of the New York Academy of Sciences 1290 (2013): 59-66.
- Madrv H., et al. “Scaffold-mediated gene delivery for osteochondral repair”. Pharmaceutics 12 (2020): 930.
- Lu DY and Che JY. “Bone disease treatments, technical advances”. EC Orthopeadics10 (2020): 1-3.
- Lu DY., et al. “Bone disease treatments, math-therapeutic modality”. EC Orthopaedics3 (2019): 140-143.
- Lu DY and Lu TR. “Drug discoveries from natural resources”. Journal of Primary Care and General Practice1 (2019): 28.
- Muthuraman A., et al. “Integration of artificial intelligence in pharmacological research with deep and machine learning process”. EC Pharmacology and Toxicology11 (2019): 56-61.
- Freedman DH. “Hunting for new drugs with AI”. Nature 576 (2019): s49-s53.
- Borrego-Gonzalez S., et al. “Sponge-like processed D-periodic self-assembled atelocollagen supports bone formation in vivo”. Materials Science and Engineering C (2020).
- Leung PC. “Traditional Chinese medicine in orthopaedics—problems and future direction”. Open Journal of Therapy and Rehabilitation1 (2014): 1-4.
- Lu DY. “Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics. 2014, Woodhead Publishing, Elsevier, UK (2014).
- Lu DY., et al. “Individualized cancer therapy, future approaches”. Current Pharmacogenomics and Personalized Medicine2 (2018): 156-163.
- Lu DY., et al. “HAART in HIV/AIDS treatments, future trends”. Infectious Disorders-Drug Targets 1 (2018): 15-22.
- Lu DY., et al. “HIV/AIDS curable study, new forms of therapeutic trinity”. Recent Patents on Anti-Infective Drug Discovery 3 (2018): 217-227.
- Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anti-Cancer Agents in Medicinal Chemistry 1 (2017): 21-28.
- Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials 3 (2017): 202-211.
- Lu DY., et al. “Individualized cancer therapy, what is the next generation?” EC Cancer 6 (2018): 286-297.
Citation
Copyright